SCHEMBL7239149

SCHEMBL7239149

CCN(CC)CC(C(C)C)(N(Cc1cccc(Br)n1)C(=O)O)C(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.32
PTGER2 P43116 5/20 0.32
FAAH O00519 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7238456 0.87 XIAP (0.34) PTGER2
SCHEMBL67697 0.78 MEN1 (0.42) SIRT2PTGER2FAAH
SCHEMBL7246524 0.72 CHRNB2 (0.30)
SCHEMBL3511520 0.72 FAAH (0.36) SIRT2PTGER2FAAH
SCHEMBL5342536 0.71 MEN1 (0.33) SIRT2FAAH
SCHEMBL14558307 0.70 MAPT (0.32) SIRT2
SCHEMBL7498162 0.70 HTR7 (0.41)
SCHEMBL6631239 0.70 SIRT2 (0.32) SIRT2
SCHEMBL5337903 0.69 CHRNB2 (0.31) SIRT2
SCHEMBL3669973 0.68 HPGD (0.40) FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6645990-B2 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases AMGEN INC. 2003-11-11 US disclosed
US-20020193405-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193405-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX SIRT2 1006/4885PTGER2 4077/4885FAAH 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.